0000899243-17-003618.txt : 20170210 0000899243-17-003618.hdr.sgml : 20170210 20170210192300 ACCESSION NUMBER: 0000899243-17-003618 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161024 FILED AS OF DATE: 20170210 DATE AS OF CHANGE: 20170210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: AESCHENVORSTADT 36 CITY: BASEL STATE: V8 ZIP: 4051 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: AESCHENVORSTADT 36 CITY: BASEL STATE: V8 ZIP: 4051 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: EMSTER KURT VON CENTRAL INDEX KEY: 0001252524 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 17595289 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD STREET 2: SUITE 350 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-10-24 0 0001674416 CRISPR Therapeutics AG CRSP 0001252524 EMSTER KURT VON C/O CRISPR THERAPEUTICS, INC. 200 SIDNEY STREET CAMBRIDGE MA 02139 1 0 0 0 Common Shares 2016-10-24 4 C 0 2354050 0.00 A 2354050 I See Footnote Common Shares 2016-10-24 4 C 0 191764 0.00 A 2545814 I See Footnote Common Shares 2016-10-24 4 P 0 56000 14.00 A 2601814 I See Footnote Series A-3 Preferred Shares 0.00 2016-10-24 4 C 0 2354050 0.00 D Common Shares 2354050 0 I See Footnote Series B Preferred Shares 0.00 2016-10-24 4 C 0 191764 0.00 D Common Shares 191764 0 I See Footnote These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date. These shares are held by Abingworth Bioventures VI, LP ("Abingworth"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. /s/ Kurt von Emster 2017-02-10